Published in J Clin Microbiol on December 09, 2009
Cryptococcus gattii infections. Clin Microbiol Rev (2014) 1.55
In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother (2010) 1.41
A diverse population of Cryptococcus gattii molecular type VGIII in southern Californian HIV/AIDS patients. PLoS Pathog (2011) 1.38
Whole genome sequence analysis of Cryptococcus gattii from the Pacific Northwest reveals unexpected diversity. PLoS One (2011) 1.33
Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect (2011) 1.31
Rapid identification of Cryptococcus neoformans var. grubii, C. neoformans var. neoformans, and C. gattii by use of rapid biochemical tests, differential media, and DNA sequencing. J Clin Microbiol (2011) 1.19
Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based method for discrimination between molecular types of Cryptococcus neoformans and Cryptococcus gattii. J Clin Microbiol (2012) 1.17
Rapid identification of Cryptococcus neoformans and Cryptococcus gattii by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol (2011) 1.15
Management of Cryptococcus gattii meningoencephalitis. Lancet Infect Dis (2014) 1.12
Cryptococcus gattii in the United States: genotypic diversity of human and veterinary isolates. PLoS One (2013) 1.10
In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype. J Clin Microbiol (2010) 1.06
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother (2012) 1.02
Fatal disseminated Cryptococcus gattii infection in New Mexico. PLoS One (2011) 0.94
The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii. Antimicrob Agents Chemother (2016) 0.88
Cryptococcus gattii as an important fungal pathogen of western North America. Expert Rev Anti Infect Ther (2012) 0.87
Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility. J Clin Microbiol (2013) 0.86
Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11. Antimicrob Agents Chemother (2013) 0.83
Antifungal drug susceptibility and phylogenetic diversity among Cryptococcus isolates from dogs and cats in North America. J Clin Microbiol (2014) 0.81
Recent Taxonomic Developments with Candida and Other Opportunistic Yeasts. Curr Fungal Infect Rep (2012) 0.80
Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans. J Antimicrob Chemother (2015) 0.79
Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India. Braz J Microbiol (2015) 0.79
Time-course proteome analysis reveals the dynamic response of Cryptococcus gattii cells to fluconazole. PLoS One (2012) 0.79
Real-time PCR assays for genotyping of Cryptococcus gattii in North America. BMC Microbiol (2014) 0.75
Prolonged incubation period for Cryptococcus gattii infection in cat, Alaska, USA. Emerg Infect Dis (2013) 0.75
Fluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11. Antimicrob Agents Chemother (2015) 0.75
Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil. Eur J Clin Microbiol Infect Dis (2016) 0.75
Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol (1982) 6.78
A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A (2004) 6.21
Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol (1984) 5.74
Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature (2005) 5.11
Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis (2000) 3.71
Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis (2007) 2.80
Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol (2009) 2.80
Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol (2004) 2.38
Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J Infect Dis (2009) 2.37
Characterization of environmental sources of the human and animal pathogen Cryptococcus gattii in British Columbia, Canada, and the Pacific Northwest of the United States. Appl Environ Microbiol (2006) 2.12
Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group. J Clin Microbiol (1996) 2.08
Comparative gene genealogies indicate that two clonal lineages of Cryptococcus gattii in British Columbia resemble strains from other geographical areas. Eukaryot Cell (2005) 1.80
First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence for spread of the Vancouver Island outbreak. J Clin Microbiol (2007) 1.70
Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol (2005) 1.61
Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J Clin Microbiol (2005) 1.53
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother (2000) 1.51
Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev Iberoam Micol (2008) 1.48
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother (2008) 1.47
Molecular analysis of 311 Cryptococcus neoformans isolates from a 30-month ECMM survey of cryptococcosis in Europe. FEMS Yeast Res (2006) 1.43
Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother (2006) 1.40
In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol (2004) 1.39
Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin Infect Dis (2006) 1.33
Cryptococcus gattii in wildlife of Vancouver Island, British Columbia, Canada. J Wildl Dis (2006) 1.28
The ecology of Cryptococcus neoformans. Eur J Epidemiol (1992) 1.21
Cryptococcosis in a bottlenose dolphin (Tursiops truncatus) caused by Cryptococcus neoformans var. gattii. J Clin Microbiol (2002) 1.20
Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn Microbiol Infect Dis (2000) 1.19
Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med Mycol (2005) 0.90
In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii. Rev Iberoam Micol (1999) 0.85
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med (2012) 3.26
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis (2013) 2.71
Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis (2011) 2.26
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Skin facilitates Candida albicans mating. Infect Immun (2003) 1.99
Opaque cells signal white cells to form biofilms in Candida albicans. EMBO J (2006) 1.96
Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis (2012) 1.91
Molecular heterogeneity of developing retinal ganglion and amacrine cells revealed through single cell gene expression profiling. J Comp Neurol (2007) 1.89
Utility of (1-3)-β-D-glucan testing for diagnostics and monitoring response to treatment during the multistate outbreak of fungal meningitis and other infections. Clin Infect Dis (2013) 1.82
FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother (2010) 1.79
Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol (2012) 1.68
Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.67
Surveillance for bacterial diarrhea and antimicrobial resistance in rural western Kenya, 1997-2003. Clin Infect Dis (2006) 1.67
The closely related species Candida albicans and Candida dubliniensis can mate. Eukaryot Cell (2004) 1.57
Release of a potent polymorphonuclear leukocyte chemoattractant is regulated by white-opaque switching in Candida albicans. Infect Immun (2004) 1.46
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol (2012) 1.44
Chromosome loss followed by duplication is the major mechanism of spontaneous mating-type locus homozygosis in Candida albicans. Genetics (2005) 1.44
Relationship between switching and mating in Candida albicans. Eukaryot Cell (2003) 1.39
Time-space clustering of human brucellosis, California, 1973-1992. Emerg Infect Dis (2002) 1.37
Next-generation sequencing of Coccidioides immitis isolated during cluster investigation. Emerg Infect Dis (2011) 1.35
Whole genome sequence analysis of Cryptococcus gattii from the Pacific Northwest reveals unexpected diversity. PLoS One (2011) 1.33
Heterozygosity of genes on the sex chromosome regulates Candida albicans virulence. Mol Microbiol (2007) 1.32
Detection of fungal DNA in human body fluids and tissues during a multistate outbreak of fungal meningitis and other infections. Eukaryot Cell (2013) 1.30
Enhanced surveillance of coccidioidomycosis, Arizona, USA, 2007-2008. Emerg Infect Dis (2010) 1.26
Human exposure following Mycobacterium tuberculosis infection of multiple animal species in a Metropolitan Zoo. Emerg Infect Dis (2002) 1.26
Unique aspects of gene expression during Candida albicans mating and possible G(1) dependency. Eukaryot Cell (2005) 1.24
Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg (2008) 1.23
Zoonoses in the bedroom. Emerg Infect Dis (2011) 1.21
Coccidioidomycosis acquired in Washington State. Clin Infect Dis (2012) 1.19
Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Physicians AIDS Care (Chic) (2012) 1.19
Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol (2009) 1.18
Utility of a Luminex-based assay for multiplexed, rapid species identification of Candida isolates from an ongoing candidemia surveillance. Can J Microbiol (2010) 1.17
Whole genome sequence typing to investigate the Apophysomyces outbreak following a tornado in Joplin, Missouri, 2011. PLoS One (2012) 1.16
Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011-2013. Emerg Infect Dis (2014) 1.15
The adhesin Hwp1 and the first daughter cell localize to the a/a portion of the conjugation bridge during Candida albicans mating. Mol Biol Cell (2003) 1.14
Cryptococcus gattii in the United States: genotypic diversity of human and veterinary isolates. PLoS One (2013) 1.10
Cryptococcus gattii infections in multiple states outside the US Pacific Northwest. Emerg Infect Dis (2013) 1.09
Disseminated histoplasmosis in HIV-infected patients in South America: a neglected killer continues on its rampage. PLoS Negl Trop Dis (2013) 1.06
Presence and persistence of Coxiella burnetii in the environments of goat farms associated with a Q fever outbreak. Appl Environ Microbiol (2013) 1.06
Phased implementation of screening for cryptococcal disease in South Africa. S Afr Med J (2012) 1.05
Fungal endophthalmitis associated with compounded products. Emerg Infect Dis (2014) 1.04
Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis (2012) 1.03
Exserohilum infections associated with contaminated steroid injections: a clinicopathologic review of 40 cases. Am J Pathol (2013) 1.03
Roles of TUP1 in switching, phase maintenance, and phase-specific gene expression in Candida albicans. Eukaryot Cell (2002) 1.01
Development and evaluation of an enzyme-linked immunosorbent assay to detect Histoplasma capsulatum antigenuria in immunocompromised patients. Clin Vaccine Immunol (2009) 0.98
Screening of a large global Aspergillus fumigatus species complex collection by using a species-specific microsphere-based Luminex assay. J Clin Microbiol (2009) 0.98
Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus - United States, May 2013-August 2016. MMWR Morb Mortal Wkly Rep (2016) 0.98
Laboratory-based Salmonella surveillance in Fiji, 2004-2005. Pac Health Dialog (2005) 0.98
Development of a Luminex-based multiplex assay for detection of mutations conferring resistance to Echinocandins in Candida glabrata. J Clin Microbiol (2013) 0.97
Multilocus sequence type analysis reveals both clonality and recombination in populations of Candida glabrata bloodstream isolates from U.S. surveillance studies. Eukaryot Cell (2010) 0.97
Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008. Antimicrob Agents Chemother (2011) 0.96
Cryptococcus gattii: where do we go from here? Med Mycol (2011) 0.96
Evaluation of a rapid lateral flow immunoassay for the detection of cryptococcal antigen for the early diagnosis of cryptococcosis in HIV patients in Colombia. Med Mycol (2013) 0.96
Cryptococcus gattii: an emerging fungal pathogen in the Southeastern United States. Am J Med Sci (2012) 0.95
Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis. Int J Med Microbiol (2009) 0.95
Fatal disseminated Cryptococcus gattii infection in New Mexico. PLoS One (2011) 0.94
Preventing deaths from cryptococcal meningitis: from bench to bedside. Expert Rev Anti Infect Ther (2011) 0.93
Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob Agents Chemother (2011) 0.93
Cryptococcus gattii, Florida, USA, 2011. Emerg Infect Dis (2013) 0.92
Eastern equine encephalitis: an emerging arboviral disease threat, Maine, 2009. Vector Borne Zoonotic Dis (2011) 0.92
Mucormycosis outbreak associated with hospital linens. Pediatr Infect Dis J (2014) 0.89
Compendium of veterinary standard precautions for zoonotic disease prevention in veterinary personnel. J Am Vet Med Assoc (2008) 0.89
Notes from the field: Fatal gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement--Connecticut, 2014. MMWR Morb Mortal Wkly Rep (2015) 0.88
Transmission of Cryptococcus neoformans by Organ Transplantation. Clin Infect Dis (2011) 0.86
Benefit cost scenarios of potential oral rabies vaccination for skunks in California. J Wildl Dis (2009) 0.86
In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network. Antimicrob Agents Chemother (2011) 0.86
Coccidioides immitis identified in soil outside of its known range - Washington, 2013. MMWR Morb Mortal Wkly Rep (2014) 0.86
First reported multistate human Q fever outbreak in the United States, 2011. Vector Borne Zoonotic Dis (2013) 0.86
Sensitivity and specificity of a new cryptococcal antigen lateral flow assay in serum and cerebrospinal fluid. MLO Med Lab Obs (2013) 0.86
Dark brown is the more virulent of the switch phenotypes of Candida glabrata. Microbiology (2008) 0.85
Compendium of veterinary standard precautions for zoonotic disease prevention in veterinary personnel: National Association of State Public Health Veterinarians Veterinary Infection Control Committee 2010. J Am Vet Med Assoc (2010) 0.83
Natural cases of 2009 pandemic H1N1 Influenza A virus in pet ferrets. J Vet Diagn Invest (2010) 0.83
Do hospital microbiology laboratories still need to distinguish Candida albicans from Candida dubliniensis? J Clin Microbiol (2011) 0.82
Skunk rabies in California (1992-2003)--implications for oral rabies vaccination. J Wildl Dis (2008) 0.82
Canine and human factors related to dog bite injuries. J Am Vet Med Assoc (2008) 0.82
BD Phoenix and Vitek 2 detection of mecA-mediated resistance in Staphylococcus aureus with cefoxitin. J Clin Microbiol (2009) 0.82
Notes from the Field: Ongoing Transmission of Candida auris in Health Care Facilities - United States, June 2016-May 2017. MMWR Morb Mortal Wkly Rep (2017) 0.81
Bloodstream and non-invasive isolates of Candida glabrata have similar population structures and fluconazole susceptibilities. Med Mycol (2011) 0.81
Estimated deaths and illnesses averted during fungal meningitis outbreak associated with contaminated steroid injections, United States, 2012-2013. Emerg Infect Dis (2015) 0.81
Mycotic Infections Acquired outside Areas of Known Endemicity, United States. Emerg Infect Dis (2015) 0.80
Tickborne relapsing fever - United States, 1990-2011. MMWR Morb Mortal Wkly Rep (2015) 0.80
Recognition and diagnosis of Cryptococcus gattii infections in the United States. Emerg Infect Dis (2012) 0.80
Multilocus sequence typing of Histoplasma capsulatum in formalin-fixed paraffin-embedded tissues from cats living in non-endemic regions reveals a new phylogenetic clade. Med Mycol (2012) 0.80
Physician attitudes regarding school-located vaccination clinics. J Sch Health (2013) 0.80
Genotyping of Candida parapsilosis from three neonatal intensive care units (NICUs) using a panel of five multilocus microsatellite markers: broad genetic diversity and a cluster of related strains in one NICU. Infect Genet Evol (2012) 0.80
Coccidioidomycosis: knowledge, attitudes, and practices among healthcare providers--Arizona, 2007. Med Mycol (2011) 0.79
New normal values not related to age and sex, of glomerular filtration rate by (99m)Tc-DTPA renal dynamic imaging, for the evaluation of living kidney graft donors. Hell J Nucl Med (2012) 0.79
Whole-Genome Analysis of Cryptococcus gattii, Southeastern United States. Emerg Infect Dis (2016) 0.79
Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine. Vaccine (2012) 0.79
Draft Genome Sequence of Mortierella alpina Isolate CDC-B6842. Genome Announc (2014) 0.79